AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound of formula (I)



(I)

wherein ring A ~~and ring B each independently~~ represents a ~~cyclic group~~ benzene ring which may have a substituent(s) wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl, ethyl, a fluorine atom, a chlorine atom, methoxy, ethoxy, difluoromethoxy, hydroxy, acetyl, trifluoromethoxy, methylsulfonyl, acetylamino, methylsulfonylamino, 1-hydroxy-1-methylethyl, 1-propenyl, and cyano;

ring B represents a benzene ring which may have a substituent(s), a thiophene ring which may have a substituent(s) an indan ring which may have a substituent(s), a 1,3-benzodioxole ring which may have a substituent(s), a cyclopentane ring which may have a substituent(s), a cyclohexane ring which may have a substituent(s), or a cyclopheptane ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl, ethyl propyl, a fluorine atom, a chlorine atom, methoxy, and ethoxy;

~~K, Q and M each independently~~ represents ~~a bond or a spacer having from 1 to 8 atoms in its principle chain~~ C1-4 alkylene which may be substituted with 1 to 5 of optional substituent(s) selected from the group consisting of methyl, a fluorine atom, hydroxy, and oxo;

Q represents methylene, ethylene, -O-, or $-CH_2-O-$;

M represents a bond, C1-4 alkylene which may have a substituent(s), or C2-4 alkenylene which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl and hydroxy;

ring D ~~and ring E each independently~~ represents ~~a cyclic group which may have a substituent(s)~~a benzene ring which may have a substituent(s), a pyrrole ring which may have a substituent(s), an imidazole ring which may have a substituent(s), a pyrazole ring which may have a substituent(s), an oxazole ring which may have a substituent(s), a thiazole ring which may have a substituent(s), or a thiophene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of carboxy, methyl, a fluorine atom, a chlorine atom, methoxylcarbonyl, ethoxycarbonyl, aminocarbonyl N-methylaminocarbonyl, N,N-dimethylaminocarbonyl, and acetyl;

ring E represents a benzene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl, a chlorine atom, a fluorine atom, methoxy, and ethoxy;

L represents a bond, ~~or a spacer having from 1 to 3 atoms in its principle chain~~ $-CH_2-$, -O-, -S-, -SO-, $-SO_2-$ or -NH-;

Z represents ~~an acidic group which may be protected~~ -COOH; $-CONHSO_2R^1$, in which R^1 represents C1-8 alkyl which may be substituted, a benzene ring which may have a substituent(s), or a pyridine ring which may have a substituent(s), a thiophene ring which may have a

substituent(s), a furan ring which may have a substituent(s), an imidazole ring which may have a substituent(s), a thiazole ring which may have a substituent(s), an isoxazole ring which may have a substituent(s), a morpholine ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 of optional substituent(s) selected from the group consisting of methyl, tert-butyl, a chlorine atom, a fluorine atom, trifluoromethyl, methoxy, trifluoromethoxy, and acetyl; and

t represents 0 or 1, or

a salt thereof, or a solvate thereof ~~or a prodrug thereof~~.

2. (Original): The compound according to claim 1, wherein the compound of formula (I) is an optically active compound of formula (I-A):



(I-A)

wherein ◤ represents β-configuration; and other symbols have the same meanings as described in claim 1.

3.-4. **(canceled).**

5. (Original): The compound according to claim 1, wherein ring B is an indane ring which may have a substituent(s).

6. (currently amended): The compound according to claim 1, wherein Q is methylene ~~which may be substituted~~ or ethylene ~~which may be substituted~~.

7. (Original) The compound according to claim 1, wherein ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s).

8. (canceled).

9. (Original) The compound according to claim 1, wherein



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted.

10. (currently amended): The compound according to claim 1,

wherein ring A is a benzene ring which may have a substituent(s);

ring B is an indane ring which may have a substituent(s);

ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s);



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted; and

Z is -COOH; $-CONHSO_2R^1$, in which R^1 C1-8 alkyl which may be substituted, a benzene ring which may have a substitutent(s)~~is an aliphatic hydrocarbon group which may be substituted or a cyclic group which may have a substituted, or tetrazolyl~~.

11. (Original) The compound according to claim 1, which is selected from the group consisting of:

(1) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,

(2) (1-{(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)(hydroxy)methyl]-5-thien-3-ylpentyl}-1H-pyrrol-3-yl)acetic acid,

(3) {1-[(2S,3S)-2-(1,3-benzodioxol-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,

(4) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}acetic acid,

(5) {1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,

(6) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid,

(7) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(8) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}propanoic acid,

(9) 3-{1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(10) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoic acid,

(11) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-N-(methylsulfonyl)acetamide,

(12) [1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-4-(methoxylcarbonyl)-1H-pyrrol-3-yl]acetic acid,

(13) N-(3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}propanoyl)-2-methylbenzenesulfonamide,

(14) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acrylic acid,

(15) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrol-3-yl}-2-methylpropanoic acid, and

(16) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}-2-methylacrylic acid.

12. (currently amended): A pharmaceutical composition comprising the compound of formula (I) according to claim 1, a salt thereof, or a solvate thereof ~~or a prodrug thereof~~, and a pharmaceutically acceptable diluent or carrier.

13. (currently amended): The pharmaceutical composition according to claim 12, which is an LPA receptor antagonist, wherein the LPA receptor is an EDG-2 receptor.

14. (canceled).

15. (currently amended): The pharmaceutical composition according to claim 12, which is an agent for ~~prevention and/or~~ treatment ~~for~~ of urinary system disease~~, carcinoma-associated disease, proliferative disease, inflammation/immune system disease, disease caused by secretory dysfunction, brain-related disease or chronic disease~~.

16. (currently amended): A method for ~~prevention and/or~~ treatment of ~~EDG-2 related diseases~~ urinary system disease, which comprises administering to a mammal an effective amount of the compound of formula (I) according to claim 1, a salt thereof, or a solvate thereof ~~or a prodrug thereof~~.

17. (canceled).

18. (currently amended): A pharmaceutical composition comprising a combination of the compound of formula (I) according to claim 1, a salt thereof, or a solvate thereof ~~or a prodrug~~

~~thereof~~ with at least one agent selected from an LPA receptor antagonist, an α1 blocking agent, an anticholinergic agent, a 5α-reductase inhibitor and an anti-androgenic agent.